Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.
Type:
Grant
Filed:
April 12, 2019
Date of Patent:
March 15, 2022
Assignee:
PHILOGEN S.P.A.
Inventors:
Roberto De Luca, Francesca Pretto, Sarah Wulhfard
Abstract: Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.
Type:
Grant
Filed:
April 1, 2019
Date of Patent:
February 15, 2022
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Tzuhua Dennis Lin, Stuart B. Goodman, Sai-Wen Tang, Everett Hurteau Meyer, Magdiel Pérez Cruz
Abstract: The present disclosure includes compositions, methods, and uses for a subset of T cells, SP T (TSP) cells, which display a quiescent (G0) phenotype. Aspects of the disclosure include methods for obtaining and mobilizing TSP cells in a subject. Other aspects include methods of adoptive cell transfer in a subject utilizing TSP cells.
Abstract: Various diseases and disorders associated with cellular senescence may be treated by immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell Immunizing a subject includes administering a vaccine that comprises an AGE antigen. Vaccines against AGE-modified proteins or peptides contain an AGE antigen, an adjuvant, optional preservatives and optional excipients.
Abstract: Provided herein are compositions containing an infusion ready population of activated, allogeneic mesenchymal stem cells and one or more pharmaceutically acceptable carriers, diluents, or excipients. Also provided are methods of treating infected wounds in mammals by administering an effective amount of activated mesenchymal stem cells to the mammal.
Type:
Grant
Filed:
December 7, 2016
Date of Patent:
November 30, 2021
Assignee:
COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
Inventors:
Steven W. Dow, Lyndah Chow, Valerie Johnson
Abstract: Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three-stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells.
Type:
Grant
Filed:
May 5, 2017
Date of Patent:
November 23, 2021
Assignee:
Celularity Inc.
Inventors:
Steven A. Fischkoff, Uri Herzberg, Lin Kang, Brian Murphy, Andrea Nordberg, Vanessa Voskinarian-Berse, Keith Wilson, Xiaokui Zhang, Han Myint, Mohamad Hussein, Robert J Hariri
Abstract: The present invention relates to a method for activating tumor-infiltrating lymphocytes (TILs) in a subject in need, particularly by administering to the subject a fermented composition generated via fermentation of symbiotic microbiota in a medium.
Type:
Grant
Filed:
January 9, 2019
Date of Patent:
November 23, 2021
Assignee:
MICROBIO CO., LTD.
Inventors:
Kung-Ming Lu, Min-Liang Kuo, Ai-Jen Yang
Abstract: The present invention relates to novel methods for the isolation and the selective ex vivo expansion of V?2? TCR??+T cells and to their clinical application.
Abstract: The present disclosure relates to a method for detecting T helper cell or CTL subpopulations in a subject affected by disease or disorder having an immune component. The methods are also useful for determining efficacy of a treatment of the disease or disorder by detecting skewing of the T helper cells and CTLs in a therapeutic or adverse direction.
Type:
Grant
Filed:
December 17, 2018
Date of Patent:
October 26, 2021
Assignee:
AMGEN INC.
Inventors:
Kevin Gorski, Jane R. Parnes, Jeannette Bigler, Michael J. Boedigheimer, Andrew A. Welcher
Abstract: The present invention provides microparticles that induce the migration of multipotent stem cells to the anatomical site of the microparticles. Various release profiles are demonstrated that depend upon the relative concentration of alginate in the chemokine-loaded microparticle. Local administration and/or intraarticular injection of the microparticles are useful in conditions such as osteoarthritis. Targeted systemic delivery of the alginate chemokine microparticles to distant anatomical sites subjected to autoimmune disease symptomology can be performed by encapsulation within liposomes having targeting ligands. Consequently, upon the creation of the appropriate chemokine gradient, multipotent stem cells will migrate to the distant anatomical site where the liposomes are attached.
Type:
Grant
Filed:
January 7, 2019
Date of Patent:
September 28, 2021
Assignees:
UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, RI.MED FOUNDATION
Inventors:
Steven R. Little, Riccardo Gottardi, Mintai Peter Hwang, Daniel DeSantis
Abstract: The present application provides methods and processes for making and using a mesenchymal stem cell secretome, as well as methods for treating ocular conditions and/disorders with the mesenchymal stem cell secretome described herein.
Abstract: Disclosed are a pharmaceutical composition for treatment of endometrium damage, a composition for enhancing implantation ability, and a pharmaceutical composition for prevention or treatment of infertility or subfertility. The pharmaceutical composition for treatment of endometrium damage includes decidual endometrial stromal cells and hyaluronic acid, the composition for enhancing implantation ability includes decidual endometrial stromal cells and hyaluronic acid, and the pharmaceutical composition for prevention or treatment of infertility or subfertility includes decidual endometrial stromal cells and hyaluronic acid.
Type:
Grant
Filed:
September 26, 2017
Date of Patent:
September 14, 2021
Assignee:
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Abstract: It is intended to disclose an antibody which binds to DLL3 protein. Preferably, the antibody of the present invention recognizes a region from amino acids 216 to 492 in human DLL3 having the amino acid sequence as set forth in SEQ ID NO: 1. The present invention also provides a pharmaceutical composition, for example, an anticancer agent, comprising the antibody of the present invention as an active ingredient. The present invention further discloses a method for diagnosing cancer using the antibody of the present invention and a diagnostic drug for cancer comprising the antibody of the present invention.
Type:
Grant
Filed:
September 4, 2015
Date of Patent:
September 7, 2021
Assignees:
CHUGAI SEIYAKU KABUSHIKI KAISHA, THE UNIVERSITY OF TOKYO
Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a mutant of tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) or Extra-Domain B (EDB) of fibronectin. The conjugate may be used in the treatment of cancer.
Type:
Grant
Filed:
November 8, 2017
Date of Patent:
August 31, 2021
Inventors:
Dario Neri, Roberto De Luca, Sarah Wulhfard
Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.
Type:
Grant
Filed:
December 9, 2020
Date of Patent:
August 31, 2021
Assignee:
The Walter and Eliza Hall Institute of Medical Research
Inventors:
Nicholas D. Huntington, Sandra E. Nicholson, Jeff Babon, Tatiana Kolesnik
Abstract: Various aspects of the invention relate to compositions comprising polycytotoxic T cells. Some aspects relate to methods for obtaining a composition comprising polycytotoxic T cells. Some aspects relate to methods of administering a composition comprising polycytotoxic T cells to a subject. Some aspects relate to methods for monitoring an immune response in a subject, comprising determining the concentration of polycytotoxic T cells in the blood of the subject. Some aspects relate to methods for treating a condition or disease in a subject, comprising administering to the subject a composition comprising an antibody, or an antigen-binding portion thereof, that specifically binds to a protein expressed by a polycytotoxic T cell.
Type:
Grant
Filed:
April 4, 2017
Date of Patent:
August 24, 2021
Assignees:
The Regents of the University of California, ULM UNIVERSITY
Inventors:
Samuel J. Balin, Robert L. Modlin, Steffen Stenger, Matteo Pellegrini
Abstract: The invention provides compositions and methods for brown fat induction and activity through modulation of Fndc5 activity and/or expression. Also provided are methods for preventing or treating metabolic disorders in a subject through modulation of Fndc5 activity and/or expression. Further provided are methods for identifying compounds that are capable of modulating Fndc5 activity and/or expression.
Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Type:
Grant
Filed:
November 28, 2018
Date of Patent:
July 27, 2021
Assignee:
NOVO NORDISK A/S
Inventors:
Anette Henriksen, Kristian Kjaergaard, Vibeke Westphal Stennicke, Charlotte Wiberg
Abstract: The present invention provides TREM2 constructs. TREM2 constructs of the invention are polynucleotide sequences encoding a polypeptide, wherein the polypeptide comprises at least one TREM2 or fragment thereof and a targeting moiety and optionally comprising a signal peptide and/or a purification moiety. The present invention also provides isolated polypeptides encoded by TREM2 constructs, vectors comprising TREM2 constructs, isolated cells comprising said vectors, and methods of use thereof.
Type:
Grant
Filed:
February 24, 2017
Date of Patent:
July 20, 2021
Assignee:
Washington University
Inventors:
Marco Colonna, Yarning Wang, Marina Celia